DK0513832T3 - Anvendelse af dibutyladipat og isopropylmyristat i topiske og transdermale produkter - Google Patents

Anvendelse af dibutyladipat og isopropylmyristat i topiske og transdermale produkter

Info

Publication number
DK0513832T3
DK0513832T3 DK92108286T DK92108286T DK0513832T3 DK 0513832 T3 DK0513832 T3 DK 0513832T3 DK 92108286 T DK92108286 T DK 92108286T DK 92108286 T DK92108286 T DK 92108286T DK 0513832 T3 DK0513832 T3 DK 0513832T3
Authority
DK
Denmark
Prior art keywords
dibutyl adipate
isopropyl myristate
topical
transdermal products
transdermal
Prior art date
Application number
DK92108286T
Other languages
Danish (da)
English (en)
Inventor
Prakash V Parab
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DK0513832T3 publication Critical patent/DK0513832T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Birds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
DK92108286T 1991-05-17 1992-05-15 Anvendelse af dibutyladipat og isopropylmyristat i topiske og transdermale produkter DK0513832T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70194491A 1991-05-17 1991-05-17
US79093991A 1991-11-12 1991-11-12

Publications (1)

Publication Number Publication Date
DK0513832T3 true DK0513832T3 (da) 2000-09-18

Family

ID=27106880

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92108286T DK0513832T3 (da) 1991-05-17 1992-05-15 Anvendelse af dibutyladipat og isopropylmyristat i topiske og transdermale produkter

Country Status (13)

Country Link
EP (1) EP0513832B1 (enExample)
JP (1) JP3331414B2 (enExample)
AT (1) ATE194919T1 (enExample)
AU (1) AU660017B2 (enExample)
CA (1) CA2068763C (enExample)
DE (1) DE69231287T2 (enExample)
DK (1) DK0513832T3 (enExample)
ES (1) ES2148158T3 (enExample)
GR (1) GR3034417T3 (enExample)
IE (1) IE921573A1 (enExample)
MX (1) MX9202235A (enExample)
PT (1) PT513832E (enExample)
TW (1) TW218849B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4335933C2 (de) * 1993-10-21 1998-09-03 Stockhausen Chem Fab Gmbh Hautreinigungsmittel
US5420106A (en) * 1994-03-22 1995-05-30 Bristol-Myers Squibb Company Method and composition having enhanced alpha-hydroxy acid skin permeation and retention
JP3576608B2 (ja) 1994-11-15 2004-10-13 日東電工株式会社 貼付剤および貼付製剤
US5702720A (en) * 1995-12-22 1997-12-30 Minnesota Mining And Manufacturing Company Transdermal device for the delivery of flurbiprofen
DE19616539A1 (de) * 1996-04-25 1997-11-06 Luitpold Pharma Gmbh Acetylsalicylsäure enthaltende alkoholische Lösungen zur perkutanen Anwendung, deren Verwendung zur antithrombotischen Therapie sowie Arzneimittel
US5990100A (en) * 1998-03-24 1999-11-23 Panda Pharmaceuticals, L.L.C. Composition and method for treatment of psoriasis
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
ATE324880T1 (de) 2002-12-18 2006-06-15 Besins Int Lab Behandlung von mastalgie mit4-hydroxy-tamoxifen
WO2004087123A1 (en) 2003-04-01 2004-10-14 Laboratoires Besins International Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
DE60327363D1 (de) 2002-12-18 2009-06-04 Besins Int Lab Verringerung der dichte des brustgewebes durch 4-hydroxy tamoxifen
ES2304610T3 (es) 2003-06-09 2008-10-16 Ascend Therapeutics, Inc. Tratamiento y prevencion de cicatrizacion excesiva con 4-hidroxi-tamoxifeno.
HUP0303313A2 (hu) * 2003-10-09 2005-07-28 Richter Gedeon Vegyészeti Gyár Rt. Transzdermális gyógyszerkészítmények
US7968532B2 (en) 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
US7507769B2 (en) 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
WO2006028835A2 (en) * 2004-09-01 2006-03-16 Trustees Of Boston University Use of thyroid hormone conversion inhibitors
CA2624788C (en) 2005-10-12 2011-04-19 Unimed Pharmaceuticals, Llc Improved testosterone gel and method of use
WO2007046315A1 (ja) * 2005-10-17 2007-04-26 Nisshin Kyorin Pharmaceutical Co., Ltd. 皮膚外用剤
WO2009015366A2 (en) * 2007-07-26 2009-01-29 Trustees Of Boston University Use of thyroid hormone conversion inhibitors to treat hyperproliferative disorders
US11957753B2 (en) 2010-11-22 2024-04-16 Bausch Health Ireland Limited Pharmaceutical formulations containing corticosteroids for topical administration
US8809307B2 (en) 2010-11-22 2014-08-19 Dow Pharmaceutical Sciences, Inc. Pharmaceutical formulations containing corticosteroids for topical administration
US20140112959A1 (en) * 2012-10-18 2014-04-24 MiCal Pharmaceuticals LLC - H Series, a Series of MiCal Pharmaceuticals LLC, a Multi-Division Limite Topical steroid composition and method
CN108282998B (zh) * 2015-06-18 2021-07-06 凡利亚药品北美公司 用于治疗银屑病的包含皮质类固醇和类视黄醇的局部组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU84059A1 (fr) * 1982-03-31 1982-07-08 Glaxo Group Ltd Nouvelles compositions pharmaceutiques comprenant des steroides anti-inflammatoires
US4678663A (en) * 1984-02-06 1987-07-07 Nuetrogena Corporation Hydroquinone composition having enhanced bio-availability and percutaneous adsorption
AU601528B2 (en) * 1986-12-22 1990-09-13 Ortho-Mcneil Pharmaceutical, Inc. Resilient transdermal drug-delivery device and compositions and devices employing fatty acid esters/ethers of alkanediols and percutaneous absorption enhancers
ATE109357T1 (de) * 1988-02-26 1994-08-15 Riker Laboratories Inc Transdermales estradiol als therapeutisches sytem.
US4988679A (en) * 1989-01-03 1991-01-29 Leonard Chavkin Liquid sustained release composition
JP2593714B2 (ja) * 1989-09-20 1997-03-26 株式会社 林原生物化学研究所 色白剤

Also Published As

Publication number Publication date
CA2068763C (en) 2001-07-31
GR3034417T3 (en) 2000-12-29
IE921573A1 (en) 1992-11-18
EP0513832B1 (en) 2000-07-26
CA2068763A1 (en) 1992-11-18
JPH05178764A (ja) 1993-07-20
DE69231287T2 (de) 2001-03-15
TW218849B (enExample) 1994-01-11
JP3331414B2 (ja) 2002-10-07
DE69231287D1 (de) 2000-08-31
AU660017B2 (en) 1995-06-08
EP0513832A1 (en) 1992-11-19
ATE194919T1 (de) 2000-08-15
MX9202235A (es) 1993-05-01
AU1632792A (en) 1992-11-19
PT513832E (pt) 2000-11-30
ES2148158T3 (es) 2000-10-16

Similar Documents

Publication Publication Date Title
DK0513832T3 (da) Anvendelse af dibutyladipat og isopropylmyristat i topiske og transdermale produkter
FI953533L (fi) Transdermaalinen terapeuttinen järjestelmä, jossa on galantamiinia vaikuttavana aineena
MX9304710A (es) Composicion farmaceutica y/o cosmetica y su uso.
TW276254B (enExample)
DE69226491D1 (de) Verbesserung der Durchdringungfähigkeit von topischen Anwendbaren Formulierungen
ZA909512B (en) Transdermal flux enhancers in combination with iontophoresis in topical administration of pharmaceuticals
NO20002422L (no) Penetrasjonsforsterkende og irritasjonssenkende systemer
DE69431209D1 (de) Transdermale prostaglandin-zusammensetzung
DK0535327T3 (da) Farmaceutisk præparat indeholdende felbinac
NO941770D0 (no) Substituert mono- og bipyridylmetylpyridon
AU4089889A (en) Method of treating skin injuries using thromboxane a2 receptor antagonists
FI961282L (fi) Transdermaalinen terapeuttinen systeemi, jossa on asetyylisalisyylihappo vaikuttavana aineena
DE69029625D1 (de) Verwendung von Retinoiden zur Umkehr glucocorticoid-induzierter Hautatrophie
FI950165A7 (fi) Ihon läpäisevä terapeuttinen järjestelmä, jossa vaikuttavana aineena o n 17-beta-estradioli (vedetön)
ATE99541T1 (de) Reizvermeidende und desensibilisierende zusammensetzungen und verfahren zu deren anwendung.
FI962550L (fi) Deuterisoidut vaikuttavat aineet transdermaalisessa käyttötarkoituksessa
DK0388275T3 (da) Dermatologiske og kosmetoligiske præparater, der er baseret på alkylcarboxamid og zinksalte og er nyttige til behandling af serborrhoisk dermatitis og/eller serborrhoiske lidelser
ATE108993T1 (de) Lichtschutz.
DE68922660D1 (de) 19-Substituierte Progesterone als 19-Hydroxylase-Inhibitoren.
ZA91115B (en) Topical compositions
DE59000613D1 (de) Pflaster zur transdermalen anwendung.
ATE113828T1 (de) Kosmetische zusammensetzung.
ATE73784T1 (de) Fungizide 2-anilinthiazoline.
ITMI912466A1 (it) Uso di 1, 2 dipalmitoil-l-alfa-fosfatidil-n, n-dimetiletanolammina, in composizioni dermatologiche
AU8132587A (en) Penetration enhancers for transdermal delivery of systemic agents